Research context · not guidance
BPC-157 and TB-500 Dosage in the Research Literature
What was administered to which species, by which route, in the underlying studies — filed as research context. There is no validated human or blend dose.
BPC-157 TB-500 dosage: what the studies used
BPC-157 TB-500 dosage has no validated value for the blend, for either constituent in humans, or for any combination. What the record contains is the doses used in animal experiments, expressed per body weight, plus a handful of single-agent human reference points for full-length Thymosin Beta-4. None of it is a human-use instruction, and none of it describes the blend.
On the BPC-157 side, rodent studies commonly express dose per body weight, frequently around 10 microg/kg and 10 ng/kg; the flagship transected-Achilles tendon work used 10 microg/kg or 10 ng/kg intraperitoneally [1]. On the TB-500 side, the underlying work used full-length Thymosin Beta-4 across a wide range — for example 150 micrograms twice weekly intraperitoneally for 6 months in a muscular-dystrophy model [4]. Commercial "Wolverine" vials pair the two at fixed combined masses (commonly ~10 mg + ~10 mg), but no peer-reviewed combination dose-finding study supports any such number.
Half-Life and Pharmacokinetics
The half-life and pharmacokinetics of the blend are unestablished. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study; no validated human pharmacokinetic half-life exists for it at research-use doses [9][11]. For the TB-500 side, human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide itself, and none for the blend [4].
The practical consequence is that no dosing interval for the combination can be derived from pharmacokinetics, because the combination has never been characterized. Community schedules are built on extrapolation, not measured clearance.
Oral vs Injectable BPC-157 and TB-500 in Research Handling
BPC-157 TB-500 oral handling is a frequent question, and the record splits by constituent. BPC-157 is studied as a relatively stable "gastric" peptide and has been investigated peroral in animal models [1]. TB-500 and its parent Thymosin Beta-4 are studied predominantly by parenteral routes — intraperitoneal in the underlying rodent work, intravenous in human Thymosin Beta-4 Phase 1 studies [4]. Oral blend products are marketed but lack validated pharmacokinetics.
The predominant research-community routes for the blend itself are subcutaneous and intramuscular, but those do not come from controlled human efficacy trials — they come from community practice. Local, intra-lesional, and topical routes appear in the individual-compound wound and tendon models [1][5].
Reconstitution and Cycling in Research Handling
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. A common community practice is to reconstitute the two peptides separately or in a shared vial. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, which compounds the existing identity caveat around TB-500 — the heptapeptide versus full-length Thymosin Beta-4 [4][8]. This is research-handling context, not a human-use instruction.